The market is still pricing Tesla, Inc. (NASDAQ:TSLA) like robotaxis are around the corner. But the real risk isn't whether autonomy works—it's whether the economics show up before the bill does.
A Spending Curve Racing Ahead
Responding to Benzinga, Counterpoint Research pegs Tesla's next phase of autonomy at a steep cost—$20–50 billion for initiatives like Terafab and expanding AI compute infrastructure. That's a massive capital ramp for a business where robotaxi revenue is still largely theoretical.
The problem isn't ambition. It's timing.
Counterpoint notes that if delays push out commercialization, the strain shifts back to Tesla's core EV business—where demand remains uneven and margins are already under pressure.
As their senior analyst Murtuza Ali puts it, "The true risk for Tesla lies not in the company's autonomous vehicle technology's failure, but in the widening gap between massive spending and revenue."
Delays Over Execution
Over the next 12–24 months, Counterpoint expects Tesla's stock to be driven less by flawless execution—and more by whether it avoids delays. Regulatory friction and hardware cycles, including AI5 timelines, could slow rollout. And in this phase, even strong tech doesn't translate into scale without approvals and infrastructure.
What investors need now isn't vision—it's proof: fleet growth, geographic expansion, operating economics, and safety metrics.
Ali underscores that shift: "Tesla is expected to have a huge spotlight on its execution… measured by fleet size, geographic expansion, operating economics and safety metrics."
Pressure Builds Beneath The Story
Tesla's autonomy narrative remains intact—but it's getting more expensive to sustain.
The bottom line: if spending keeps accelerating while revenue lags, the gap becomes harder to ignore.
And in that scenario, Tesla's biggest challenge isn't building robotaxis—it's justifying the cost of getting there.
Photo: Tada Images / Shutterstock
Photo: Tada Images / Shutterstock
Login to comment